Translating the effect of dual lipid reduction with PCSK9 inhibitors on a mechanical vascular instrumental biomarker in familial hypercholesterolemia subjects. [PDF]
Bosco G +13 more
europepmc +1 more source
Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction. [PDF]
Cars T +13 more
europepmc +1 more source
Mendelian randomization analysis of lipid-lowering drug targets and neuropsychiatric disorders. [PDF]
Peng S, Liu M, Du F, Li K.
europepmc +1 more source
Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. [PDF]
Deo SV +11 more
europepmc +1 more source
Obicetrapib and renal function: A welcome signal, but not yet a kidney story. [PDF]
Barkas F, Ray KK.
europepmc +1 more source
Managing Progressive Atherosclerotic Cardiovascular Disease in a Patient with Elevated Lipoprotein(a). [PDF]
Yurtseven E, Tokgözoğlu L.
europepmc +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 Induces Platelet-Derived Transforming Growth Factor-<i>β</i> to Promote Myocardial Fibrosis After Myocardial Infarction. [PDF]
Wang Q, Huang W, Xia D, Wang F, Nair S.
europepmc +1 more source
Integrative Proteomic and Lipidomic Analysis of Patients With Acute Myocardial Infarction Treated With PCSK9 Antibodies and Statins. [PDF]
Schmidt LE +15 more
europepmc +1 more source
Influence of PCSK9 inhibitors on early neurological function, inflammatory factors and blood lipids in patients with acute cerebral infarction: a retrospective cohort study. [PDF]
Peng H +7 more
europepmc +1 more source
Advanced therapy in familial hypercholesterolemia. [PDF]
Gao E, Brunham LR, Goldman RD.
europepmc +1 more source

